EUVIMEDEUVIMED entdecken
VergleichsstudieKontrollierte klinische StudieOpen Access · CC BY 4.0

Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80–250 cc: the hope trial outcome at 1 year

Shivank Bhatia, Ansh Bhatia, Andrew Richardson, Chloe Issa, Zachary Stauber, Kenneth Richardson, Muhammad U Shahid, Joao G Porto, Hemendra N Shah

World Journal of Urology · 13.01.2026 · 44 (1)

DOI: 10.1007/s00345-025-06115-0 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift World Journal of Urology, online erschienen am 13.01.2026. Verfasst von Shivank Bhatia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Interventional Radiology, University of Miami, Miller School of Medicine, 1150 NW 14 St. Suite 702, Miami, FL, 33136, USA. Hauptthemen laut MEDLINE: Embolization, Therapeutic, Laser Therapy, Lasers, Solid-State, Prostate. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

To compare outcomes of Prostate Artery Embolization (PAE) with Holmium Laser Enucleation of Prostate (HoLEP) for management of symptomatic benign prostate hyperplasia in men with prostate volume 80 to 250 cc.

Methods

In this open-label prospective clinical-trial, 45 patients were enrolled in a 2:1 ratio to undergo PAE and HoLEP, respectively. The voiding parameter, sexual function, and complications were evaluated at 1, 3, 6, and 12-months. The primary endpoint was a reduction in the International Prostate Symptom Score (IPSS) at 3 months. Secondary-outcomes were change in the International Index of Erectile Function-15 (IIEF-15), International Consultation on Incontinence Questionnaire-urinary incontinence (ICIQ-UI), Quality-of-Life (QoL), IPSS, uroflow (Qmax) and Prostate Specific Antigen (PSA). Adverse-events were recorded and graded using the Clavien–Dindo Adverse-event (CD-AE) classification.

Results

No significant difference in median IPSS and quality of life improvement was observed at any follow-up point. PAE had significantly better IIEF-15 and ICIQ-UI outcomes than HoLEP at 1 and 3 months. HoLEP outperformed PAE in PSA reduction, Qmax, and post-void residual (PVR) improvement at 3 and 12-months. However, PAE had shorter hospital stays and avoided catheterization. No major adverse events (Clavien–Dindo ≥ grade 3) occurred in either group.

Conclusion

In men with BPH and prostate sizes 80–250gm, PAE and HoLEP produce similar IPSS and QoL improvement at medium-term follow-up. PAE had better IIEF-15 and ICIQ-UI, in addition to the advantage of avoiding catheterization and reduced hospital stay. HoLEP performed better in PSA reduction, Qmax, and PVR improvement at 3 and 12 months. No serious adverse events occurred in either treatment group. Small sample size and short-term follow-up were important limitations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Embolization, TherapeuticLaser TherapyLasers, Solid-StateProstateProstatic HyperplasiaAgedHumansMaleMiddle AgedArteriesOrgan SizeProspective StudiesQuality of LifeTime FactorsTreatment Outcome

Stichwörter der Autor:innen

Benign prostatic hyperplasiaHolmium laser enucleationLower urinary tract symptomsProstate artery embolization

Autor:innen und Institutionen

  • Department of Interventional Radiology, University of Miami, Miller School of Medicine, 1150 NW 14 St. Suite 702, Miami, FL, 33136, USA.
  • Florida Prostate Centers, 13722 Jog Rd. Suite A, Delray Beach, Miami, FL, 33446, USA.
  • Department of Interventional Radiology, University of Miami, Miller School of Medicine, 1150 NW 14 St. Suite 702, Miami, FL, 33136, USA. bhatia.ansh2000@gmail.com.
  • Desai Sethi Urology Institute, University of Miami, Miller School of Medicine, Miami, FL, USA.

Zitieren

APA

Bhatia, S., Bhatia, A., Richardson, A., Issa, C., Stauber, Z., Richardson, K., Shahid, M. U., Porto, J. G., & Shah, H. N. (2026). Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80–250 cc: the hope trial outcome at 1 year. World Journal of Urology, 44(1). https://doi.org/10.1007/s00345-025-06115-0

Vancouver

Bhatia S, Bhatia A, Richardson A, Issa C, Stauber Z, Richardson K, et al. Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80–250 cc: the hope trial outcome at 1 year. World Journal of Urology. 2026;44(1). doi:10.1007/s00345-025-06115-0

BibTeX
@article{Bhatia2026,
  author = {Bhatia, Shivank and Bhatia, Ansh and Richardson, Andrew and Issa, Chloe and Stauber, Zachary and Richardson, Kenneth and Shahid, Muhammad U and Porto, Joao G and Shah, Hemendra N},
  title = {Prospective, non-randomized, controlled investigation of prostate (P) artery embolization (E) compared to holmium (Ho) laser enucleation of prostate for the treatment of symptomatic benign prostatic hyperplasia with prostate volume 80–250 cc: the hope trial outcome at 1 year},
  journal = {World Journal of Urology},
  year = {2026},
  volume = {44},
  number = {1},
  doi = {10.1007/s00345-025-06115-0}
}
Kostenlos starten →